CRVS · Corvus Pharmaceuticals, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026TL;DR. Corvus reported Q2 net loss of $18.0M versus $8.0M prior year, with R&D up to $16.0M from $7.9M on soquelitinib trial costs, while cash grew to $215.2M (from $56.8M) extending runway into Q2 2028. Enrollment in the Phase 3 PTCL trial (futility analysis now expected Q1 2027) and Phase 2 atopic dermatitis trial remains on track, with Angel Pharma's atopic dermatitis cohort 1 data expected before year-end and new HS and asthma trials planned to start later this year.
- + Cash position grew to $215.2M, extending runway into Q2 2028
- + Phase 3 PTCL and Phase 2 atopic dermatitis trial enrollment remain on track
- + Phase 1 atopic dermatitis data showed 75% EASI75 in cohort 4 with durable activity and clean safety profile
- + Pipeline expanding with new hidradenitis suppurativa and asthma trials planned later this year
- + Angel Pharma cohort 1 atopic dermatitis data expected before year-end 2026
- − Q2 net loss widened to $18.0M from $8.0M year-over-year
- − R&D expenses roughly doubled to $16.0M from $7.9M on soquelitinib trial costs
- − PTCL Phase 3 futility analysis shifted from prior guidance to Q1 2027
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CRVS
this stock
Corvus Pharmaceuticals, Inc.
|
$830.27M | +32.6% | — | — | 20.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.16B | +11.0% | +46.2% | 29.5 | 1.9% |
|
MRNA
Moderna, Inc.
|
$78.65B | +568.0% | +4.3% | — | 8.2% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.14B | -4.2% | +20.8% | 18.3 | 2.5% |
|
CSLLY
Csl Ltd
|
$60.24B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CRVS | -6.6% | -21.1% | -39.0% | -11.4% | +32.6% |
| SPY | +1.3% | +2.1% | +9.0% | +1.5% | +13.5% |
| vs SPY | -7.9% | -23.2% | -48.0% | -12.9% | +19.1% |